CPT1A and neoplasm: Long-chain fatty acyl-CoA synthase 1, which catalyzes the bioconversion of exogenous or de novo synthesized fatty acids to fatty acyl-CoA, promoted tumor progression by reducing CPT1 activity and the number of prostate cancer cells remaining in the G1/S phase (41).